BioTuesdays

Tag - William Blair

MDXHealth-logo

WB starts MDxHealth at outperform

William Blair launched coverage of MDxHealth S.A. (NASDAQ:MDXH) with an “outperform” rating. The stock closed at $2.86 on March 23. Analyst Andrew Brackmann writes that the rating is based on his belief that the company...

Mesoblast-Logo

WB starts Mesoblast at OP; fair value estimate $8

William Blair initiated coverage of Mesoblast (NASDAQ:MESO) with an “outperform” rating and fair value estimate of $8. The stock closed at $3.03 on March 8. Mesoblast is developing mesenchymal lineage cell-derived...

Janux Logo

WB starts Janux Therapeutics at OP

William Blair initiated coverage of Janux Therapeutics (NASDAQ:JANX) with an “outperform” rating based on the potential of the company’s TRACTr platform, which facilitates the generation of conditionally active T-cell...

Akouos

WB starts Akouos at OP; fair value estimate $12

William Blair launched coverage of Akouos (NASDAQ:AKUS) with an “outperform” rating and fair value estimate of $12. The stock closed at $5.10 on Sept. 28. Akouos is developing a pipeline of gene therapies delivered...

Point Biopharma Logo

WB starts POINT Biopharma at outperform

William Blair initiated coverage of POINT Biopharma Global (NASDAQ:PNT) with an “outperform” rating based on a view that the Street is “underestimating the clinical and commercial potential of the company’s...

Arcellx

WB starts Arcellx at OP; fair value estimate $40

William Blair initiated coverage of Arcellx (NASDAQ:ACLX) with an “outperform” rating and fair value estimate of $40. The stock closed at $16.94 on Feb. 28. Arcellx’s next-generation cell therapy platform is founded on...